Effects of Multivitamin and Mineral Supplements on Biological Age in Healthy Middle-aged Individuals

Centrum; the Effect of Daily Intake of Multivitamin & Mineral Supplementation, on Biological Age in Relatively Healthy Middle-aged Individuals (CEDIRA)

This study is testing whether daily multivitamin and mineral supplements can help middle-aged people feel younger biologically than their actual age.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 400 (estimated)
• Ages: 40 Years to 60 Years
• Sex: All
• Sponsor: National University of Singapore (Academic / other)
• Locations: 2 sites (Singapore, Singapore and 1 other locations)
• Trial ID: NCT06666660 on ClinicalTrials.gov

What this trial studies

This study evaluates the impact of daily multivitamin and mineral supplementation on the biological age of relatively healthy middle-aged individuals, specifically those whose biological age exceeds their chronological age. Participants will be randomly assigned to receive either the supplements or a placebo in a double-blind manner. The study will measure biological age using DNA methylation clocks, which are established biomarkers of aging. The goal is to determine if supplementation can effectively lower biological age and improve health outcomes.

Who should consider this trial

Good fit: Ideal candidates are relatively healthy men and women aged 40-60 with a biological age greater than their chronological age.

Not a fit: Patients with chronic diseases or those outside the specified BMI range may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a novel approach to reducing biological age and potentially lowering the risk of age-related diseases in middle-aged individuals.

How similar studies have performed: Previous studies have shown that specific vitamins can positively influence biological age, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria

Participants will be recruited if they fall in the following categories:

1. Relatively healthy middle aged (40-60 years) man or woman;
2. Completed the pre-screening requirements and has managed to schedule the screening visit;
3. Met the randomization criteria after the screening visit i.e., your biological age (as measured by blood DNA methylation) is greater than the chronological age;
4. Able to attend all 4 research visits for screening and research data collection at the NUHS Centre for Healthy Longevity (CHL) at Alexandra Hospital or MD11, National University of Singapore.
5. Willing to wear an OURA ring for 14 consecutive days after each study visits.
6. Willing to download study platform application into their mobile phone throughout the study period.

Exclusion Criteria

Participants will NOT be recruited if they fall in any one or more of the following categories:

1. BMI lower than 18 kg/m2 or higher than or equal to 30 kg/m2 \[25\];
2. Pre-existing, or history of major cardiovascular diseases (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (more than 1 prescribed medication), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism;
3. Type 1 diabetes and Type 2 diabetes;
4. Active cancer or treatment of cancer in the last 3 years;
5. Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications);
6. Pregnant women or women planning pregnancy in the next 12 months;
7. Multiple sclerosis or autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease;
8. Recent history of sepsis or infection (within 3 months of in-patient hospitalisation);
9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders;
10. Hepatitis and liver cirrhosis (independent of severity);
11. Severe kidney disease (GFR less than 30 ml/min/1.73 m2);
12. Skin disease (on systemic medication);
13. Individuals who are on another trial that requires them taking similar or partially similar investigational product (Appendix 1);
14. Individuals who are advised by their medical practitioner to take a MVM supplement;
15. Refuse to stop taking any non-prescribed supplements that contain the investigational product (Appendix 1) within one month before the screening visit and during the study period;
16. Taking a medically prescribed supplements that contains 2 or more of the ingredients of the investigational product (Appendix 1);
17. Individuals with planned hospitalization in the next 12 months;
18. Any serious medical illness which in the PI's judgment may jeopardise the participant by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.

Where this trial is running

Singapore, Singapore and 1 other locations

• Healthy Longevity Translational Research Programme, Level 3, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore — Singapore, Singapore, Singapore (Recruiting)
• Center for Healthy Longevity, Clinic L, Alexandra Hospital, 378 Alexandra Road — Singapore, Singapore, Singapore (Recruiting)

Study contacts

• Principal investigator: Andrea Britta Maier, MD PhD FRACP — National University of Singapore
• Study coordinator: Andrea Britta Maier, MD PhD FRACP

Conditions Relatively Healthy Volunteers; multivitamin; supplement; randomized controlled trial; biological age; DNA methylation; Epigenetic age